NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CamGene Therapeutics

CamGene Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://camgenetx.com/

Last Round

Seed

Oct 29, 2025

Company Overview

CamGene Therapeutics is a biotechnology company developing RNA-based therapeutics designed to address the underlying cellular dysfunction that causes hearing loss.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

lipid nanoparticleLNPRNA therapeuticshearing loss treatmentdrug deliverycochlear regenerationmRNA therapysiRNAantisense oligonucleotideASOinner ear therapybiotech startupregenerative medicinegene therapyhearing tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CamGene Therapeutics Comparables

Compare CamGene Therapeutics with similar companies based on industry and business-model similarity.

CamGene Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rinri Therapeutics
79%
Spiral Therapeutics
76%
Suzhou Otovia Therapeutics Co., Ltd.
71%

CamGene Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 29, 2025
Pre SeedApr 5, 2024

Key People

Founding team and executive leadership

Arpan Desai

Chief Executive Officer

Executive Team

Paul McKay

Chief Technology Officer

Executive Team

CamGene Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 7, 2026

    Grew 60% QoQ from 5 to 8 employees.

CamGene Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CamGene Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CamGene Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range9
Year Founded2023
Last FundingOct 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.